One dose may not fit all: blood tests could tailor cancer drug dosing
NCT ID NCT05443087
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By tracking drug levels over time and linking them to outcomes, researchers hope to develop a model that predicts the optimal dose for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Blood sampling to measure levels of multikinase inhibitors (regorafenib, everolimus, sunitinib, cabozantinib, encorafenib-cetuximab) in the blood
- What this could lead to
- If successful, this could lead to personalized dosing of these cancer drugs, improving effectiveness and reducing side effects for each patient.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly test whether adjusted dosing improves outcomes. The results may not apply to all patients or drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIGESTIVE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP Pitié Salpétrière
RECRUITINGParis, France
-
CH Eure Seine - Hopital d'Evreux Vernon
NOT_YET_RECRUITINGÉvreux, France
-
CH Saint Malo - Hôpital Broussais
RECRUITINGSt-Malo, France
-
CH d'Auxerre
RECRUITINGAuxerre, France
-
CH de Bayeux - Onconormandie
WITHDRAWNBayeux, France
-
CHRU de Nancy - Hôpital de Brabois Adulte
RECRUITINGNancy, France
-
CHU Rouen - Hôpital Charles Nicolle
RECRUITINGRouen, France
-
CHU d'Amiens Pcardie - Hopital Sud
RECRUITINGAmiens, France
-
CHU de Nantes - Hôtel Dieu
RECRUITINGNantes, France
-
CHU de Poitiers
NOT_YET_RECRUITINGPoitiers, France
-
CHU de Reims - Hôpital Robert Debré
RECRUITINGReims, France
-
CHU de Tours
RECRUITINGTours, France
-
Centre Antoine Lacassagne
WITHDRAWNNice, France
-
Centre Eugène Marquis
NOT_YET_RECRUITINGRennes, France
-
Centre Georges Francois Leclerc
WITHDRAWNDijon, France
-
Centre Jean Perrin
RECRUITINGClermont-Ferrand, France
-
Centre Léon Bérard
WITHDRAWNLyon, France
-
Centre Oscar Lambret
RECRUITINGLille, France
-
Groupement des hôpitaux de l'Institut Catholique de Lille - Hôpital Saint Vincent de Paul
NOT_YET_RECRUITINGLille, France
-
Gustave Roussy
RECRUITINGVillejuif, France
-
Hôpital Beaujon APHP
RECRUITINGClichy, France
-
Hôpital Européen Marseille
NOT_YET_RECRUITINGMarseille, France
-
Hôpital Privé des Côtes d'Armor - SAS
RECRUITINGPlérin, France
-
Hôpital Saint Joseph
RECRUITINGParis, France
-
ICANS
RECRUITINGStrasbourg, France
-
Institut Jean Godinot
RECRUITINGReims, France
-
Institut Mutualiste de Montsouris
RECRUITINGParis, France
-
Institut de Cancérologie de Bourgogne
RECRUITINGDijon, France
-
Institut du Cancer Avignon - Institut Sainte Catherine
WITHDRAWNAvignon, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Do Younger-Age pancreatic tumors behave differently? a new study digs in
- Can delivering cancer drug directly to the liver shrink tumors?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?